OLIT vs. AXDX, DAIO, STAI, ASTC, PRPO, BNGO, TLIS, TBIO, SMIT, and SPEC
Should you be buying OmniLit Acquisition stock or one of its competitors? The main competitors of OmniLit Acquisition include Accelerate Diagnostics (AXDX), Data I/O (DAIO), Scantech AI Systems (STAI), Astrotech (ASTC), Precipio (PRPO), Bionano Genomics (BNGO), Talis Biomedical (TLIS), Telesis Bio (TBIO), Schmitt Industries (SMIT), and Spectaire (SPEC). These companies are all part of the "measuring and control equipment" industry.
OmniLit Acquisition vs.
Accelerate Diagnostics (NASDAQ:AXDX) and OmniLit Acquisition (NASDAQ:OLIT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.
OmniLit Acquisition has lower revenue, but higher earnings than Accelerate Diagnostics.
Accelerate Diagnostics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, OmniLit Acquisition has a beta of 0.05, suggesting that its stock price is 95% less volatile than the S&P 500.
In the previous week, Accelerate Diagnostics had 2 more articles in the media than OmniLit Acquisition. MarketBeat recorded 2 mentions for Accelerate Diagnostics and 0 mentions for OmniLit Acquisition. Accelerate Diagnostics' average media sentiment score of 0.72 beat OmniLit Acquisition's score of 0.00 indicating that Accelerate Diagnostics is being referred to more favorably in the media.
Accelerate Diagnostics currently has a consensus price target of $1.00, suggesting a potential downside of 14.16%. Given Accelerate Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe Accelerate Diagnostics is more favorable than OmniLit Acquisition.
OmniLit Acquisition has a net margin of 0.00% compared to Accelerate Diagnostics' net margin of -471.83%.
Accelerate Diagnostics received 355 more outperform votes than OmniLit Acquisition when rated by MarketBeat users.
17.1% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 21.6% of OmniLit Acquisition shares are held by institutional investors. 43.6% of Accelerate Diagnostics shares are held by company insiders. Comparatively, 78.0% of OmniLit Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Accelerate Diagnostics beats OmniLit Acquisition on 9 of the 13 factors compared between the two stocks.
Get OmniLit Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for OLIT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OmniLit Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:OLIT) was last updated on 3/12/2025 by MarketBeat.com Staff
